Verrica Pharmaceuticals Reveals Acceptance Of A Late-breaking Abstract Reporting Phase 2 Exploratory Data Of VP-315; Data To Be Presented At The Upcoming 2026 Society for Investigative Dermatology Annual Meeting
Benzinga Newsdesk 7 months ago
BiotechNewsGeneral
Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced acceptance
Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced acceptance of a late-breaking abstract reporting Phase 2 exploratory data of VP-315, Verrica's novel oncolytic peptide for the treatment of basal cell carcinoma. The data will be presented at the upcoming 2026 Society for Investigative Dermatology (SID) Annual Meeting, which will take place from May 13-16, 2026, in Chicago, Illinois.